Rahul Dev manages the Pharmaceutical and Biotechnology Patent Practice at Tech Corp Law Group. He is a Patent attorney and intellectual property lawyer with 11+ years of experience in Biotechnology, Pharmaceuticals, Healthcare, Medical Devices, Drug Patent Search and Chemicals in international markets (US, Europe, Asia Pacific and MENA region).
How to get medicine drug patent in India? Law Office of Rahul Dev provides freedom to operate FTO strategy for medicinal drugs to patent attorneys worldwide
Why to file patent to protect new marketing management tool? 5 Great Steps to follow #patents #business Ask patent attorney
Joshi Prabhakr Anant, Joshi Salil Prabhakar was Granted Patent For A Lock Assembly Published By Indian Patent Office, Will filing a patent application under PCT grant worldwide patent protection?
It would be interesting to note the outcome of the meetings. However, it would be interesting to note whether the US pharma lobby will be able to influence the way India's patent offices and judiciary interpret India's patent law. meeting with the patent officials will provide the Intellectual Property Owners' Association (IPOA) members better overview on how to draft the pharmaceutical patent applications to be filed in India. The pharma and medicine based innovations should include data related to therapeutic efficacy to obviate section 3d of the Indian Patent Act. However, it is surprising to note that the Intellectual Property Owners' Association (IPOA) members are being allowed to meet the judiciary. In a recent case the Supreme Court seriously viewed the allegation of 2G scam accused and coal scam accused meeting the CBI director Ranjit Sinha.
Pharmaceutical companies employ patent extension strategies to compensate for their R&D investments and regulatory approval costs of new drugs. Broadly, three major extensions and protections exist, namely, Supplementary Protection Certificates (SPCs), Patent Term Extensions (PTEs), and Regulatory Data Protection (RDP).
Practically in India if a "X" company patented invention is not available at an affordable price to the public at large after two years from the grant date, section 85 of the Indian Patent Act can be invoked to grant compulsory licence. Therefore, the onus to avoid revocation in India is with the patent assignee to develop methodology to keep the price of medicines cost effective and make it available to the general public.
Medical Device Patent Attorney | Medical Device Intellectual Property Lawyer
Top Patent filers & Patent recipients classified under IPC C12: Genentech, Novartis, Monsanto, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, PIONEER HI-BRED INTERNATIONAL, INC., NOVARTIS AG, Monsanto Technology LLC, ROCHE DIAGNOSTICS GMBH